Did anyone catch the exact wording at around the 6:30 minute mark when talking about Sandoz profit share in a scenario with an authorized generic? Seeking Alpha has it as "(inaudible)". I think it is "hybrid economics" but want to be sure Wheeler didn't give more of a hint. TIA
This is the seeking alpha text at around the 6:30 minute mark.
If the only competitor to M-Enoxaparin is an authorized generic, we received (inaudible) and royalty up to a specified sales level, then a profit share on net sales above the sales cut off.
Market Data 
Markets 
AI
